Beam Therapeutics IPO
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing technology. The company's platform enables single letter changes in DNA without double-strand breaks, potentially offering safer gene editing approaches. Investors are interested in its differentiated technology and pipeline addressing liver diseases, blood disorders, and ocular conditions.
What We Know
Beam Therapeutics completed its IPO in February 2020, raising approximately $180 million on NASDAQ under the ticker BEAM. The company priced its shares at $17 each, reflecting strong investor appetite for next-generation gene editing technologies beyond traditional CRISPR approaches. Since going public, Beam has advanced its base editing programs through preclinical and early clinical development. The stock has shown the volatility characteristic of clinical-stage biotech companies, with performance often tied to clinical updates and broader sentiment toward gene editing companies. The company has also established strategic partnerships to advance its pipeline.
Frequently Asked Questions
Has Beam Therapeutics had an IPO?
Yes, Beam Therapeutics completed its IPO in February 2020. The company has been publicly traded on NASDAQ under the ticker BEAM since then.
When is the Beam Therapeutics IPO date?
Beam Therapeutics already completed its IPO on February 6, 2020. The company is currently trading as a public biotechnology stock on NASDAQ.
How can I buy Beam Therapeutics stock?
You can buy Beam Therapeutics stock through any brokerage account since it trades publicly on NASDAQ under the ticker BEAM. The stock is available for purchase during regular trading hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts